;PMID: 10698361
;source_file_824.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..155] = [t:42..155]
;2)section:[e:159..225] = [t:159..225]
;3)section:[e:229..347] = [t:229..347]
;4)sentence:[e:351..539] = [t:351..539]
;5)sentence:[e:540..704] = [t:540..704]
;6)sentence:[e:705..838] = [t:705..838]
;7)sentence:[e:839..972] = [t:839..972]
;8)sentence:[e:973..1044] = [t:973..1044]
;9)sentence:[e:1046..1165] = [t:1046..1165]
;10)sentence:[e:1166..1311] = [t:1166..1311]
;11)section:[e:1315..1360] = [t:1315..1360]

;section 0 Span:0..36
;Life Sci. 2000 Jan 21;66(9):PL133-9.
(SEC
  (FRAG (NNP:[0..4] Life) (NNP:[5..8] Sci) (.:[8..9] .) (CD:[10..14] 2000)
        (CC:[15..18] Jan) (CD:[19..26] 21;66-LRB-9) (-RRB-:[26..27] -RRB-)
        (CD:[27..33] :PL133) (HYPH:[33..34] -) (CD:[34..36] 9.)))

;sentence 1 Span:42..155
;Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and
;3A4  activity in healthy volunteers.
;[52..67]:substance:"St. John's wort"
;[69..89]:substance:"Hypericum perforatum"
;[94..114]:cyp450:"cytochrome P-450 2D6"
;[94..110]...[119..122]:cyp450:"cytochrome P-450"..."3A4"
(SENT
  (NP-HLN
    (NP (NN:[42..48] Effect))
    (PP (IN:[49..51] of)
      (NP
        (NP
          (NP (NNP:[52..55] St.) (NNP:[56..60] John) (POS:[60..62] 's))
          (NN:[63..67] wort))
        (NP (-LRB-:[68..69] -LRB-)
           (NNP:[69..78] Hypericum) (NNP:[79..89] perforatum)
          (-RRB-:[89..90] -RRB-))))
    (PP (IN:[91..93] on)
      (NP
        (NP
          (NML
            (NML-1 (NN:[94..104] cytochrome) (NN:[105..110] P-450))
            (NN:[111..114] 2D6))
          (NML-2 (-NONE-:[114..114] *P*)))
        (CC:[115..118] and)
        (NP
          (NML
            (NML-1 (-NONE-:[118..118] *P*))
            (NN:[119..122] 3A4))
          (NML-2 (NN:[124..132] activity)))))
    (PP-LOC (IN:[133..135] in)
      (NP (JJ:[136..143] healthy) (NNS:[144..154] volunteers)))
    (.:[154..155] .)))

;section 2 Span:159..225
;Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC.
(SEC
  (FRAG (NNP:[159..168] Markowitz) (NNP:[169..171] JS) (,:[171..172] ,)
        (NNP:[173..179] DeVane) (NNP:[180..182] CL) (,:[182..183] ,)
        (NNP:[184..191] Boulton) (NNP:[192..194] DW) (,:[194..195] ,)
        (NNP:[196..202] Carson) (NNP:[203..205] SW) (,:[205..206] ,)
        (NNP:[207..212] Nahas) (NNP:[213..214] Z) (,:[214..215] ,)
        (NNP:[216..221] Risch) (NNP:[222..224] SC) (.:[224..225] .)))

;section 3 Span:229..347
;Department of Pharmaceutical Sciences, Medical University of South Carolina, 
;Charleston 29425, USA. markowij@musc.edu
(SEC
  (FRAG (NNP:[229..239] Department) (IN:[240..242] of)
        (NNP:[243..257] Pharmaceutical) (NNP:[258..266] Sciences)
        (NNP:[266..267] ,) (NNP:[268..275] Medical) (NNP:[276..286] University)
        (IN:[287..289] of) (NNP:[290..295] South) (NNP:[296..304] Carolina)
        (,:[304..305] ,) (NNP:[307..317] Charleston) (CD:[318..323] 29425)
        (,:[323..324] ,) (NNP:[325..328] USA) (.:[328..329] .)
        ('':[330..347] markowij@musc.edu)))

;sentence 4 Span:351..539
;The effects of the herb St. John's wort (Hypericum perforatum), a purported 
;antidepressant, on the activity of cytochrome P-450 (CYP) 2D6 and 3A4 was 
;assessed in seven normal volunteers.
;[375..390]:substance:"St. John's wort"
;[392..412]:substance:"Hypericum perforatum"
;[428..442]:substance:"antidepressant"
;[463..489]:cyp450:"cytochrome P-450 (CYP) 2D6"
;[463..485]...[494..497]:cyp450:"cytochrome P-450 (CYP)"..."3A4"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[351..354] The) (NNS:[355..362] effects))
      (PP (IN:[363..365] of)
        (NP
          (NP
            (NP (DT:[366..369] the) (NN:[370..374] herb))
            (NP
              (NP
                (NP (NNP:[375..378] St.) (NNP:[379..383] John)
                    (POS:[383..385] 's))
                (NN:[386..390] wort))
              (NP (-LRB-:[391..392] -LRB-)
                 (NNP:[392..401] Hypericum) (NNP:[402..412] perforatum)
                (-RRB-:[412..413] -RRB-))))
          (,:[413..414] ,)
          (NP (DT:[415..416] a) (VBN:[417..426] purported)
              (NN:[428..442] antidepressant))))
      (,:[442..443] ,)
      (PP (IN:[444..446] on)
        (NP
          (NP (DT:[447..450] the) (NN:[451..459] activity))
          (PP (IN:[460..462] of)
            (NP
              (NP
                (NML-1
                  (NML (NN:[463..473] cytochrome) (NN:[474..479] P-450))
                  (NML (-LRB-:[480..481] -LRB-) (NN:[481..484] CYP)
                       (-RRB-:[484..485] -RRB-)))
                (NN:[486..489] 2D6))
              (CC:[490..493] and)
              (NP
                (NML-1 (-NONE-:[493..493] *P*))
                (NN:[494..497] 3A4)))))))
    (VP (VBD:[498..501] was)
      (VP (VBN:[503..511] assessed)
        (NP-2 (-NONE-:[511..511] *))
        (PP-LOC (IN:[512..514] in)
          (NP (CD:[515..520] seven) (JJ:[521..527] normal)
              (NNS:[528..538] volunteers)))))
    (.:[538..539] .)))

;sentence 5 Span:540..704
;Probe substrates dextromethorphan (2D6  activity) and alprazolam (3A4
;activity) were administered orally with and  without the co-administration of
;St. John's wort.
;[540..545]:substance:"Probe"
;[546..556]:substance:"substrates"
;[557..573]:substance:"dextromethorphan"
;[575..578]:cyp450:"2D6"
;[594..604]:substance:"alprazolam"
;[606..609]:cyp450:"3A4"
;[688..703]:substance:"St. John's wort"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[540..545] Probe) (NNS:[546..556] substrates))
      (NP
        (NP (NN:[557..573] dextromethorphan)
          (PRN (-LRB-:[574..575] -LRB-)
            (NP (NN:[575..578] 2D6) (NN:[580..588] activity))
            (-RRB-:[588..589] -RRB-)))
        (CC:[590..593] and)
        (NP (NN:[594..604] alprazolam)
          (PRN (-LRB-:[605..606] -LRB-)
            (NP (NN:[606..609] 3A4) (NN:[610..618] activity))
            (-RRB-:[618..619] -RRB-)))))
    (VP (VBD:[620..624] were)
      (VP (VBN:[625..637] administered)
        (NP-1 (-NONE-:[637..637] *))
        (ADVP (RB:[638..644] orally))
        (PP (IN:[645..649] with) (CC:[650..653] and) (IN:[655..662] without)
          (NP
            (NP (DT:[663..666] the) (AFX:[667..669] co) (HYPH:[669..670] -)
                (NN:[670..684] administration))
            (PP (IN:[685..687] of)
              (NP
                (NP (NNP:[688..691] St.) (NNP:[692..696] John)
                    (POS:[696..698] 's))
                (NN:[699..703] wort)))))))
    (.:[703..704] .)))

;sentence 6 Span:705..838
;Urinary concentrations of  dextromethorphan and dextrorphan were quantified
;and dextromethorphan metabolic  ratios (DMRs) determined.
;[732..748]:substance:"dextromethorphan"
;[753..764]:substance:"dextrorphan"
;[785..801]:substance:"dextromethorphan"
(SENT
  (S
    (S
      (NP-SBJ-1=3
        (NP (JJ:[705..712] Urinary) (NNS:[713..727] concentrations))
        (PP (IN:[728..730] of)
          (NP (NN:[732..748] dextromethorphan) (CC:[749..752] and)
              (NN:[753..764] dextrorphan))))
      (VP (VBD:[765..769] were)
        (VP=4 (VBN:[770..780] quantified)
          (NP-1=5 (-NONE-:[780..780] *)))))
    (CC:[781..784] and)
    (S
      (NP-SBJ-2=3
        (NP (NN:[785..801] dextromethorphan) (JJ:[802..811] metabolic)
            (NNS:[813..819] ratios))
        (NP (-LRB-:[820..821] -LRB-) (NNS:[821..825] DMRs)
            (-RRB-:[825..826] -RRB-)))
      (VP=4 (VBN:[827..837] determined)
        (NP-2=5 (-NONE-:[837..837] *))))
    (.:[837..838] .)))

;sentence 7 Span:839..972
;Plasma samples were collected (0-60 hrs) for  alprazolam pharmacokinetic
;analysis sufficient to estimate tmax, Cmax, t 1/2,  and AUC.
;[870..874]:quantitative-value:"0-60"
;[875..878]:quantitative-units:"hrs"
;[885..895]:substance:"alprazolam"
;[944..948]:quantitative-name:"tmax"
;[950..954]:quantitative-name:"Cmax"
;[956..961]:quantitative-name:"t 1/2"
;[968..971]:quantitative-name:"AUC"
(SENT
  (S
    (NP-SBJ-1 (NN:[839..845] Plasma) (NNS:[846..853] samples))
    (VP (VBD:[854..858] were)
      (VP (VBN:[859..868] collected)
        (NP-1 (-NONE-:[868..868] *))
        (PRN (-LRB-:[869..870] -LRB-)
          (NP-TMP
            (QP (CD:[870..871] 0) (HYPH:[871..872] -) (CD:[872..874] 60))
            (NNS:[875..878] hrs))
          (-RRB-:[878..879] -RRB-))
        (PP-PRP (IN:[880..883] for)
          (NP
            (NP (NN:[885..895] alprazolam) (JJ:[896..911] pharmacokinetic)
                (NN:[912..920] analysis))
            (ADJP-PRD (JJ:[921..931] sufficient)
              (S
                (NP-SBJ (-NONE-:[931..931] *))
                (VP (TO:[932..934] to)
                  (VP (VB:[935..943] estimate)
                    (NP
                      (NP (NN:[944..948] tmax))
                      (,:[948..949] ,)
                      (NP (NN:[950..954] Cmax))
                      (,:[954..955] ,)
                      (NP (NN:[956..957] t)
                        (QP (CD:[958..959] 1) (SYM:[959..960] /)
                            (CD:[960..961] 2)))
                      (,:[961..962] ,) (CC:[964..967] and)
                      (NP (NN:[968..971] AUC)))))))))))
    (.:[971..972] .)))

;sentence 8 Span:973..1044
;Validated HPLC methods were used to quantify all compounds of interest.
;[1022..1031]:substance:"compounds"
(SENT
  (S
    (NP-SBJ-1 (VBN:[973..982] Validated) (NN:[983..987] HPLC)
              (NNS:[988..995] methods))
    (VP (VBD:[996..1000] were)
      (VP (VBN:[1001..1005] used)
        (NP-1 (-NONE-:[1005..1005] *))
        (S-ADV
          (NP-SBJ (-NONE-:[1005..1005] *))
          (VP (TO:[1006..1008] to)
            (VP (VB:[1009..1017] quantify)
              (NP
                (NP (DT:[1018..1021] all) (NNS:[1022..1031] compounds))
                (PP (IN:[1032..1034] of)
                  (NP (NN:[1035..1043] interest)))))))))
    (.:[1043..1044] .)))

;sentence 9 Span:1046..1165
;No statistically significant differences were found in any estimated 
;pharmacokinetic parameter for alprazolam or DMRs.
;[1146..1156]:substance:"alprazolam"
(SENT
  (S
    (NP-SBJ-1 (DT:[1046..1048] No)
      (ADJP (RB:[1049..1062] statistically) (JJ:[1063..1074] significant))
      (NNS:[1075..1086] differences))
    (VP (VBD:[1087..1091] were)
      (VP (VBN:[1092..1097] found)
        (NP-1 (-NONE-:[1097..1097] *))
        (PP (IN:[1098..1100] in)
          (NP (DT:[1101..1104] any) (VBN:[1105..1114] estimated)
              (JJ:[1116..1131] pharmacokinetic) (NN:[1132..1141] parameter)))
        (PP (IN:[1142..1145] for)
          (NP (NN:[1146..1156] alprazolam) (CC:[1157..1159] or)
              (NNS:[1160..1164] DMRs)))))
    (.:[1164..1165] .)))

;sentence 10 Span:1166..1311
;These results suggest that St.  John's wort, when taken at recommended doses
;for depression, is unlikely to  inhibit CYP 2D6 or CYP 3A4 activity.
;[1193..1209]:substance:"St.  John's wort"
;[1283..1290]:cyp450:"CYP 2D6"
;[1294..1301]:cyp450:"CYP 3A4"
(SENT
  (S
    (NP-SBJ (DT:[1166..1171] These) (NNS:[1172..1179] results))
    (VP (VBP:[1180..1187] suggest)
      (SBAR (IN:[1188..1192] that)
        (S
          (NP-SBJ
            (NP (NNP:[1193..1196] St.) (NNP:[1198..1202] John)
                (POS:[1202..1204] 's))
            (NN:[1205..1209] wort))
          (,:[1209..1210] ,)
          (SBAR-ADV
            (WHADVP-3 (IN:[1211..1215] when))
            (S
              (NP-SBJ-1 (-NONE-:[1215..1215] *))
              (VP (VBN:[1216..1221] taken)
                (NP-1 (-NONE-:[1221..1221] *))
                (PP (IN:[1222..1224] at)
                  (NP (VBN:[1225..1236] recommended) (NNS:[1237..1242] doses)))
                (PP-PRP (IN:[1243..1246] for)
                  (NP (NN:[1247..1257] depression)))
                (ADVP-3 (-NONE-:[1257..1257] *T*)))))
          (,:[1257..1258] ,)
          (VP (VBZ:[1259..1261] is)
            (ADJP-PRD (JJ:[1262..1270] unlikely)
              (S
                (NP-SBJ (-NONE-:[1270..1270] *))
                (VP (TO:[1271..1273] to)
                  (VP (VB:[1275..1282] inhibit)
                    (NP
                      (NP
                        (NML (NN:[1283..1286] CYP) (NN:[1287..1290] 2D6))
                        (NML-2 (-NONE-:[1290..1290] *P*)))
                      (CC:[1291..1293] or)
                      (NP
                        (NML (NN:[1294..1297] CYP) (NN:[1298..1301] 3A4))
                        (NML-2 (NN:[1302..1310] activity))))))))))))
    (.:[1310..1311] .)))

;section 11 Span:1315..1360
;PMID: 10698361 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1315..1319] PMID) (::[1319..1320] :) (CD:[1321..1329] 10698361)
        (IN:[1330..1331] -LSB-) (NNP:[1331..1337] PubMed) (HYPH:[1338..1339] -)
        (JJ:[1340..1347] indexed) (IN:[1348..1351] for)
        (NNP:[1352..1360] MEDLINE-RSB-)))
